SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-12-12
Accession Number: 0001493152-25-027406
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225027406/filename1.htm

Chunk 52 of 89
Word Count: 1472
Character Count: 9931

Document Content:

since September 2022. Since early 2025, Dr. Puri has been national principal investigator for the ALLAY-HFrEF trial. He also serves on the global steering committees of multiple other pivotal trials in the aortic, mitral and tricuspid valve therapy space. Dr. Puri completed his medical degree (MBBS) and a Ph.D. in medicine/cardiology at the University of Adelaide in 2001 and 2014, respectively, during which time he also held an internship, residency, and a fellowship in internal medicine and cardiology at the Royal Adelaide Hospital.Dr. Puri then completed subspecialty training in interventional and structural heart disease at the Québec Heart and Lung Institute in Quebec City from 2014 to 2017, at the Rennes University Hospital during 2017, and was appointed visiting Senior Staff Cardiologist at Royal Adelaide Hospital in 2017 and 2018, and at the Universitätsspital Zürich in 2018.He received his FRACP degree from the Royal Australasian College of Physicians in 2008.

William T. Abraham,
M.D., FACP, FACC, FAHA, FESC, FRCPE

Dr. Abraham, age 66, has
served as a member of our board of directors since August 2025. He has also served as a member of the board of directors of scPharmaceuticals
Inc. (Nasdaq: SCPH) since February 2021.

Dr. Abraham joined Cardiac
Dimensions as Chief Medical Officer in September 2025 having served as Chief Medical Officer of V-Wave Ltd. (now a subsidiary of Johnson
& Johnson) since March 2019. Over his career, he has participated as a site principal investigator, national or international principal
investigator, and/or on the executive or steering committees in numerous multicenter clinical drug and device trials. He was the lead
author of the MIRACLE cardiac resynchronization therapy trial (2002), a principal investigator of the CHAMPION implantable hemodynamic
monitoring trial (2011), and a co-principal investigator of the COAPT percutaneous mitral valve repair trial (2018).

Dr. Abraham has authored
or co-authored more than 1,000 manuscripts, book chapters, and scientific papers published in peer-reviewed journals,
including The New England Journal of Medicine, The Lancet, and The Journal of the American Medical Association. His research
interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, sleep-disordered breathing, and
clinical drug and device trials in heart failure and cardiac transplantation.

Dr. Abraham received his
B.A. in Honors Philosophy from the University of Pittsburgh in 1982 and his M.D. from Harvard Medical School in 1986. He completed his
internal medicine residency (1986–1990) at the University of Colorado Health Sciences Center where he also completed fellowships
in cardiovascular disease and advanced heart failure/cardiac transplantation (1990–1993) and served on the faculty (1993-1997).
He then joined the faculty at the University of Cincinnati as Associate Professor of Medicine and Director, Section of Heart Failure
and Cardiac Transplantation from 1997–2000 and subsequently the University of Kentucky faculty as Chief of Cardiovascular Medicine
from 2000 to 2002. Dr. Abraham is Professor of Medicine, Physiology and Cell Biology at The Ohio State University Wexner Medical Center
having served as the Chief of Cardiovascular Medicine at The Ohio State University from 2002 to 2019. He is board-certified in internal
medicine and advanced heart failure and transplant cardiology. We believe that Dr. Abraham’s clinical-trial leadership, academic
expertise, regulatory experience, and board service at other life sciences companies qualify him to serve as a member of our board of
directors.

Family
Relationships

There
are no family relationships between or among any of the current directors, executive officers or persons nominated or charged to become
directors or executive officers.

Number
and Terms of Office of Officers and Directors

Our
business and affairs are organized under the direction of our board of directors. Upon the consummation of this offering, our board of
directors will consist of five directors, including two executive directors and three independent directors.

Our
Amended and Restated Bylaws provide that the number of directors will be fixed by the board of directors within a range of between 1
and 9 directors. The directors need not be stockholders unless so required by our certificate of incorporation. The minimum or maximum
number may be increased or decreased from time to time only by an amendment to the bylaws, which power belongs exclusively to our board
of directors.

Our
officers are appointed by the board of directors and shall hold office at the discretion of the board of directors until their successors
are duly elected and qualified, unless sooner removed. Our board of directors is authorized to appoint officers to the offices set forth
in our bylaws.

Director
Independence

The
Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined
generally as a person who has no material relationship with the listed company (either directly or as a partner, shareholder or officer
of an organization that has a relationship with our company). We have three “independent directors” as defined in the Nasdaq
listing standards and applicable SEC rules prior to completion of this offering.

Our
board has determined that Mark Ravich, Rishi Puri and William Abraham are independent directors under applicable SEC and Nasdaq
rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present.

Board
Committees

Our
board of directors has established an Audit Committee, a Nominating and Corporate Governance Committee and a Compensation Committee.
Our board of directors has adopted a charter for each of these three committees. Prior to the completion of this offering, copies of
each committee’s charter will be posted on the Investor Relations section of our website, which will be located at www.bioventrix.com.
Each of the committees of our board of directors shall have the composition and responsibilities described below. Our board of directors
may from time to time establish other committees as it deems appropriate.

Audit
Committee

Ravich, Dr. Abraham and Dr. Puri will serve as members of our Audit Committee with Mr. Ravich serving as the chairman of the Audit
Committee. Each of our Audit Committee members will
satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards under Rule 10A-3
under the Exchange Act. Our board of directors has determined that Mark Ravich possesses accounting or related financial management experience
that qualifies her as an “audit committee financial expert” as defined by the rules and regulations of the SEC. Our Audit
Committee oversees our accounting and financial reporting processes and the audits of our financial statements. Our Audit Committee will
perform several functions, including:

●	evaluating
the performance, independence and qualifications of our independent registered public accounting firm and determining whether to
retain our existing independent registered public accounting firm or engage new independent registered public accounting firm;

●	reviewing
and approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit
services;

●	reviewing
our annual and quarterly financial statements and reports, including the disclosures contained under the caption “ Management’s
Discussion and Analysis of Financial Condition and Results of Operations ,” and discussing the statements and reports with
our independent registered public accounting firm and management;

●	reviewing
with our independent registered public accounting firm and management significant issues that arise regarding accounting principles
and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;

●	reviewing
our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk
management is implemented; and

●	reviewing
and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.

Compensation
Committee

Ravich, Dr. Abraham and Dr. Puri will serve as members of our Compensation Committee with Mr. Ravich serving as the chairman of the
Compensation Committee. All of our Compensation
Committee members satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards
under Rule 10A-3 under the Exchange Act. The functions of this committee include, among other things:

●	reviewing,
modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall
compensation strategy and policies;

●	reviewing and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment
of our executive officers;

●	reviewing
and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive
plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and
programs;

●	reviewing
and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory
arrangements for our executive officers;

●	reviewing
with management and approving our disclosures under the caption “ Compensation Discussion and Analysis ” in our
periodic reports or proxy statements to be filed with the SEC; and

●	preparing
the report that the SEC requires in our annual proxy statement.

Nominating
and Corporate Governance Committee